Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

Lechleiter editorial, Chamber of Commerce appearance include warnings about adverse effects on innovation; “Odyssey Project” launched to press similar themes.

You may also be interested in...



Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine

As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.

Rx Import Legislation: One Step Forward, Two Steps Back – And Odd Dance Partners

The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.

US COVID Vaccine Authorizations: Too Much – Or Never Enough?

A US FDA advisory committee review of a novel COVID vaccine candidate from Novavax made one thing very clear: The agency is firmly convinced that when it comes to vaccine options, more is better.

Topics

Latest News
UsernamePublicRestriction

Register

PS069427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel